stock jumped to its 50-day moving average in early May after the company beat first-quarter sales expectations, thanks to a one-time benefit for Covid drug Paxlovid.
During the March quarter, the U.S. government handed back 5.1 million courses of Paxlovid, boosting sales by $771 million. Excluding that, Paxlovid still beat sales forecasts. Notably, revenue from the firm's…

#vyndaqel#nurtec#tivdak#pfizer#seagen#rsva#gsk#arexvy